IRVING, BRYAN,CHEUNG, JEANNE,CHIU, HENRY,LEHAR, SOPHIE M.,MAECKER, HEATHER,MARIATHASAN, SANJEEV,WU, YAN
申请号：
PE2014001134
公开号：
PE20141722A1
申请日:
2009.12.08
申请国别(地区):
PE
年份:
2014
代理人:
摘要：
It refers to an independent anti-PD-L1 antibody, which contains a heavy chain variable region, including a hvr-h1 sequence, which is SEQ ID No.1, hvr-h2, SEQ ID No.2, hvr-h3, which is SEQ ID No.3； it is combined with a light region chain composed of hvr-l1, which includes a hvr-l1, which is SEQ ID No.8, hvr-l2, which is SEQ ID No.9, Hvr-l3 sequence is SEQ ID n: 10 It also mentions the process of producing the antibody, which is an effective way to treat T-cell dysfunction.SE REFIERE A UN ANTICUERPO ANTI-PD-L1 AISLADO, QUE PRESENTA UNA REGION VARIABLE DE CADENA PESADA QUE COMPRENDE UNA SECUENCIA HVR-H1 QUE ES SEQ ID NO:1, HVR-H2 QUE ES SEQ ID NO: 2, HVR-H3 QUE ES SEQ ID NO: 3； Y QUE SE COMBINA CON UNA CADENA LIGERA DE REGION VARIABLE QUE COMPRENDE UNA HVR-L1 QUE ES SEQ ID NO: 8, HVR-L2 QUE ES SEQ ID NO: 9, LA SECUENCIA HVR-L3 QUE ES SEQ ID N:10. SE REFIERE TAMBIEN A UN PROCESO PARA PRODUCIR DICHO ANTICUERPO, SIENDO UTIL PARA EL TRATAMIENTO DE TRASTORNOS DISFUNCIONALES DE LA CELULA T.
